FDA Grants Priority Review to Pembrolizumab Plus Chemotherapy for Advanced Pleural Mesothelioma
The FDA has granted priority review to a new supplemental biologics license application (sBLA) seeking the approval of pembrolizumab (Keytruda) in combination with chemotherapy for the frontline treatment of patients with unresectable or metastatic …